Genmab announces responses with HuMax-CD4(TM) in non-cutaneous T-cell lymphoma
HuMax-CD38 also effective in preclinical studies: Kills Multiple Myeloma and Plasma Cell Leukemia Tumor Cells
14-Dec-2005 -
Genmab A/S announced preliminary results in the Phase II study using HuMax-CD4TM to treat patients with refractory or relapsed non-cutaneous T-cell lymphoma. At week 6, according to the Cheson criteria, 3 patients achieved objective responses as assessed by CT scan and clinical investigation, ...
antibodies
chemotherapy
cytotoxicity
+4